Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 8Phase NA 5Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 33Prostatic Neoplasms 32Neoplasms 29Multiple Myeloma 25Pancreatic Neoplasms 24Brain Neoplasms 22Colorectal Neoplasms 18Recurrence 17Squamous Cell Carcinoma of Head and Neck 16Melanoma 15Lung Neoplasms 14Neoplasm Metastasis 13Lymphoma, B-Cell 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Sarcoma 12Lymphoma 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Leukemia, Myeloid, Acute 11Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Lymphoma, Non-Hodgkin 9Skin Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 8Colonic Neoplasms 8

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pathologic Complete Response × 1 year × Clear all
NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡